ResMed Inc. (NYSE:RMD) Receives Average Recommendation of "Moderate Buy" from Analysts

ResMed Inc. (NYSE:RMD - Get Free Report) has earned a consensus rating of "Moderate Buy" from the fifteen analysts that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $244.73.

RMD has been the subject of a number of research reports. The Goldman Sachs Group started coverage on ResMed in a research report on Thursday, January 16th. They set a "buy" rating for the company. KeyCorp boosted their price objective on shares of ResMed from $266.00 to $280.00 and gave the company an "overweight" rating in a research report on Friday, January 31st. Stifel Nicolaus started coverage on shares of ResMed in a research report on Friday, December 13th. They issued a "hold" rating and a $250.00 target price for the company. JPMorgan Chase & Co. boosted their price target on shares of ResMed from $270.00 to $286.00 and gave the company an "overweight" rating in a report on Friday, January 31st. Finally, StockNews.com upgraded ResMed from a "hold" rating to a "buy" rating in a report on Tuesday, October 15th.

ResMed Trading Down 2.3 %

Shares of NYSE:RMD traded down $5.47 during mid-day trading on Monday, hitting $237.11. The stock had a trading volume of 992,644 shares, compared to its average volume of 1,030,356. The company's 50 day moving average is $239.68 and its 200-day moving average is $237.19. ResMed has a 12-month low of $170.56 and a 12-month high of $263.05. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.29 and a current ratio of 3.33. The company has a market cap of $34.81 billion, a PE ratio of 27.99, a P/E/G ratio of 1.69 and a beta of 0.70.

ResMed (NYSE:RMD - Get Free Report) last released its earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.29 by $0.14. ResMed had a return on equity of 26.17% and a net margin of 25.34%. On average, sell-side analysts predict that ResMed will post 9.41 EPS for the current year.

ResMed Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 13th will be issued a $0.53 dividend. The ex-dividend date is Thursday, February 13th. This represents a $2.12 annualized dividend and a yield of 0.89%. ResMed's dividend payout ratio (DPR) is currently 25.03%.

Insiders Place Their Bets

In other ResMed news, Director Peter C. Farrell sold 2,000 shares of the firm's stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $242.11, for a total value of $484,220.00. Following the sale, the director now owns 77,218 shares of the company's stock, valued at $18,695,249.98. This trade represents a 2.52 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Witte Jan De sold 796 shares of the company's stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $248.81, for a total value of $198,052.76. Following the transaction, the director now owns 6,723 shares of the company's stock, valued at approximately $1,672,749.63. This trade represents a 10.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 11,094 shares of company stock valued at $2,704,941 over the last 90 days. 0.71% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On ResMed

Several hedge funds and other institutional investors have recently modified their holdings of RMD. Howard Capital Management Inc. increased its holdings in shares of ResMed by 5.3% in the fourth quarter. Howard Capital Management Inc. now owns 900 shares of the medical equipment provider's stock valued at $206,000 after purchasing an additional 45 shares in the last quarter. UMB Bank n.a. lifted its stake in ResMed by 1.9% in the third quarter. UMB Bank n.a. now owns 2,465 shares of the medical equipment provider's stock valued at $602,000 after buying an additional 47 shares during the period. Ascent Group LLC boosted its stake in ResMed by 1.7% during the 3rd quarter. Ascent Group LLC now owns 2,924 shares of the medical equipment provider's stock worth $714,000 after acquiring an additional 48 shares during the last quarter. SkyView Investment Advisors LLC grew its holdings in shares of ResMed by 2.0% in the 3rd quarter. SkyView Investment Advisors LLC now owns 2,610 shares of the medical equipment provider's stock valued at $637,000 after buying an additional 51 shares during the period. Finally, Wedmont Private Capital raised its stake in ResMed by 2.6% during the 4th quarter. Wedmont Private Capital now owns 2,032 shares of the medical equipment provider's stock worth $475,000 after buying an additional 52 shares during the period. Institutional investors and hedge funds own 54.98% of the company's stock.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.